CAMP4 Therapeutics (CAMP) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

CAMP4 Therapeutics (CAMP) overview

CAMP4 Therapeutics (CAMP) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 3.5m and operating profit of USD -52.6m; the year-end share price was 6.13 USD and market capitalisation was USD 318m. CAMP4 Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get CAMP4 Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 47.7mFY 2025
Share price6.13 USDFY 2025 year end
RevenueUSD 3.5mFY 2025
Operating profitUSD -52.6mFY 2025
Net earningsUSD -80.4mFY 2025
Market capitalisationUSD 318mFY 2025 year end

About CAMP4 Therapeutics

CAMP4 Therapeutics develops RNA-targeting therapeutics intended to increase gene expression and restore protein levels in genetic diseases. Its lead candidate, CMP-002, is an antisense oligonucleotide designed to increase SYNGAP1 expression and is in preclinical development for SYNGAP1-related disorder. The company uses its RAP Platform to identify regulatory RNAs and generate candidates, focusing on central nervous system diseases and additional discovery programs.

Generate the CAMP4 Therapeutics report

CAMP4 Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for CAMP4 Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on CAMP4 Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.